[Federal Register Volume 66, Number 74 (Tuesday, April 17, 2001)]
[Notices]
[Pages 19787-19788]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-9453]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60 Day-01-30]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the CDC Reports 
Clearance Officer on (404) 639-7090.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Send comments to Anne O'Connor, CDC 
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, 
Atlanta, GA 30333. Written comments should be received within 60 days 
of this notice.
    Proposed Project: Gonococcal Isolate Surveillance Project (GISP) 
(0920-0307)--Extension--The National Center for HIV, STD, and TB 
Prevention (NCHSTP), Centers for Disease Control and Prevention (CDC) 
proposes to continue data collection for the Gonococcal Isolate 
Surveillance Project (OMB No. 0920-0307). This request is a three-year 
extension of clearance.
    The purposes of the Gonococcal Isolate Surveillance Project (GISP) 
are (1) to monitor trends in antimicrobial susceptibility of strains of 
Neisseria gonorrhoeae in the United States and (2) to characterize 
resistant isolates. GISP provides critical surveillance for 
antimicrobial resistance, allowing for informed treatment 
recommendations. GISP was begun in 1986 as a voluntary surveillance 
project and now involves five regional laboratories and 26 publicly 
funded sexually transmitted disease (STD) clinics around the country. 
The STD clinics submit up to 25 gonococcal isolates per month to the 
regional laboratories, which measure susceptibility to a panel of 
antibiotics. Limited demographic and clinical information corresponding 
to the isolates are submitted directly by the clinics to CDC.
    Data gathered through GISP are used to alert the public health 
community to changes in antimicrobial resistance in Neisseria 
gonorrhoeae which may impact treatment choices, and to guide 
recommendations made in CDC's STD Treatment Guidelines, which are 
published periodically.
    Under the GISP protocol, clinics are asked to provide 25 isolates 
per month. However, due to low volume at some sites, clinics submit an 
average of 17 isolates per clinic per month, providing an average of 88 
isolates per laboratory per month. The estimated time for clinic 
personnel to abstract data is 11 minutes per response. Based on 
previous laboratory experience in analyzing gonococcal isolates, we 
estimate 88 gonococcal isolates per laboratory each month. The 
estimated burden for each participating laboratory is one hour per 
response. Averaged over 88 isolates per laboratory per month, the 
estimated time for recording control strain data is 0.34 minutes per 
response. There is no cost to respondents.

[[Page 19788]]



----------------------------------------------------------------------------------------------------------------
                                                                 No. of         Avg. burden/
               Respondents                     No. of         respondents/      response (in      Total  burden
                                             respondents        response            hrs.)           (in hrs.)
----------------------------------------------------------------------------------------------------------------
Laboratory..............................                 5   1,056 (12 x 88)             1.006             5,312
Clinic..................................                26     204 (12 x 17)             11/60               972
                                         ------------------                                    -----------------
      Total.............................                31  ................  ................             6,284
----------------------------------------------------------------------------------------------------------------


    Dated: April 11, 2001.
Nancy E. Cheal,
Acting Associate Director for Policy, Planning, and Evaluation, Centers 
for Disease Control and Prevention (CDC).
[FR Doc. 01-9453 Filed 4-16-01; 8:45 am]
BILLING CODE 4163-18-P